Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. more
Time Frame | ERNA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -20.12% | -3.72% | -0.05% |
1-Month Return | -60.64% | -1.85% | 2.75% |
3-Month Return | -82.01% | -11.4% | 7.4% |
6-Month Return | -86.21% | -4.41% | 10.47% |
1-Year Return | -80.46% | 4.13% | 27.57% |
3-Year Return | -99.72% | 0.3% | 29.56% |
5-Year Return | -99.75% | 36.62% | 89.3% |
10-Year Return | -99.94% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 19.81M | 5.80M | - | - | 68.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":29.28,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":0.34,"profit":true}] |
Cost of Revenue | 7.84M | 98.00K | 459.00K | 497.00K | 236.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":1.25,"profit":true},{"date":"2021-12-31","value":5.85,"profit":true},{"date":"2022-12-31","value":6.34,"profit":true},{"date":"2023-12-31","value":3.01,"profit":true}] |
Gross Profit | 11.96M | (98.00K) | (459.00K) | (497.00K) | (168.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.82,"profit":false},{"date":"2021-12-31","value":-3.84,"profit":false},{"date":"2022-12-31","value":-4.15,"profit":false},{"date":"2023-12-31","value":-1.4,"profit":false}] |
Gross Margin | 60.40% | (1.69%) | (Infinity%) | (Infinity%) | (247.06%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2.8,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":-409.03,"profit":false}] |
Operating Expenses | 13.18M | 7.25M | 27.43M | 27.23M | 20.73M | [{"date":"2019-12-31","value":48.03,"profit":true},{"date":"2020-12-31","value":26.42,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.26,"profit":true},{"date":"2023-12-31","value":75.58,"profit":true}] |
Operating Income | (1.21M) | (7.25M) | 68.34M | (33.22M) | (21.14M) | [{"date":"2019-12-31","value":-1.77,"profit":false},{"date":"2020-12-31","value":-10.61,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-48.6,"profit":false},{"date":"2023-12-31","value":-30.93,"profit":false}] |
Total Non-Operating Income/Expense | - | (19.33M) | (95.13M) | 8.65M | (630.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-223.34,"profit":false},{"date":"2021-12-31","value":-1099.34,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-7.28,"profit":false}] |
Pre-Tax Income | (2.02M) | (7.29M) | (122.30M) | (24.53M) | (21.67M) | [{"date":"2019-12-31","value":-202000000,"profit":false},{"date":"2020-12-31","value":-729100000,"profit":false},{"date":"2021-12-31","value":-12230100000,"profit":false},{"date":"2022-12-31","value":-2453400000,"profit":false},{"date":"2023-12-31","value":-2167100000,"profit":false}] |
Income Taxes | 27.00K | (19.20M) | 5.00K | 45.00K | (3.00K) | [{"date":"2019-12-31","value":60,"profit":true},{"date":"2020-12-31","value":-42660,"profit":false},{"date":"2021-12-31","value":11.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-6.67,"profit":false}] |
Income After Taxes | - | 11.91M | (122.31M) | (24.58M) | (21.67M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1027.26,"profit":false},{"date":"2022-12-31","value":-206.44,"profit":false},{"date":"2023-12-31","value":-181.99,"profit":false}] |
Income From Continuous Operations | - | (7.29M) | (122.31M) | (24.58M) | (20.00M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-729100000,"profit":false},{"date":"2021-12-31","value":-12230600000,"profit":false},{"date":"2022-12-31","value":-2457900000,"profit":false},{"date":"2023-12-31","value":-2000400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (2.05M) | 11.91M | (122.31M) | (24.58M) | (21.67M) | [{"date":"2019-12-31","value":-17.19,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1027.26,"profit":false},{"date":"2022-12-31","value":-206.44,"profit":false},{"date":"2023-12-31","value":-181.99,"profit":false}] |
EPS (Diluted) | (0.71) | 0.16 | (5.62) | (8.13) | - | [{"date":"2019-12-31","value":-443.75,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3512.5,"profit":false},{"date":"2022-12-31","value":-5081.25,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
ERNA | |
---|---|
Cash Ratio | 0.43 |
Current Ratio | 0.48 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ERNA | |
---|---|
ROA (LTM) | -29.42% |
ROE (LTM) | -1154.18% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ERNA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 6.88 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -5.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ERNA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 91.65 |
P/B | 2.10 |
Price/FCF | NM |
EV/R | 73.80 |
EV/Ebitda | NM |
Eterna Therapeutics Inc (ERNA) share price today is $0.2716
Yes, Indians can buy shares of Eterna Therapeutics Inc (ERNA) on Vested. To buy Eterna Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ERNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Eterna Therapeutics Inc (ERNA) via the Vested app. You can start investing in Eterna Therapeutics Inc (ERNA) with a minimum investment of $1.
You can invest in shares of Eterna Therapeutics Inc (ERNA) via Vested in three simple steps:
The 52-week high price of Eterna Therapeutics Inc (ERNA) is $2.63. The 52-week low price of Eterna Therapeutics Inc (ERNA) is $0.27.
The price-to-earnings (P/E) ratio of Eterna Therapeutics Inc (ERNA) is
The price-to-book (P/B) ratio of Eterna Therapeutics Inc (ERNA) is 2.10
The dividend yield of Eterna Therapeutics Inc (ERNA) is 0.00%
The market capitalization of Eterna Therapeutics Inc (ERNA) is $14.85M
The stock symbol (or ticker) of Eterna Therapeutics Inc is ERNA